Statin use and patterns of breast cancer recurrence in the Malmö Diet and Cancer Study
(2022) In Breast 61. p.123-128- Abstract
Background: Accumulating evidence suggests that statins have a beneficial effect on breast cancer prognosis. Previous studies have reported a positive association between statin use and breast cancer survival; however, the relationship between statin use and patterns of breast cancer recurrence remains unclear. Patients and methods: We identified all Malmö Diet and Cancer Study (MDCS) participants diagnosed with incident invasive breast cancer between 2005 and 2014. The follow-up period began at breast cancer diagnosis and continued until the first invasive breast cancer recurrence event, death, emigration or the end of the follow-up (June 8, 2020). We estimated incidence rates (IRs) of recurrence and fit Cox regression models to... (More)
Background: Accumulating evidence suggests that statins have a beneficial effect on breast cancer prognosis. Previous studies have reported a positive association between statin use and breast cancer survival; however, the relationship between statin use and patterns of breast cancer recurrence remains unclear. Patients and methods: We identified all Malmö Diet and Cancer Study (MDCS) participants diagnosed with incident invasive breast cancer between 2005 and 2014. The follow-up period began at breast cancer diagnosis and continued until the first invasive breast cancer recurrence event, death, emigration or the end of the follow-up (June 8, 2020). We estimated incidence rates (IRs) of recurrence and fit Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CIs) for disease recurrence to compare post-diagnosis statin users with non-users. Results: The final study cohort consisted of 360 eligible patients with a median follow-up of 8.6 years. Overall, there were 71 recurrences in 2932 total person-years. According to statin use, there were 14 recurrences in 595 person-years among statin users, and 57 recurrences in 2337 person-years in non-users. Statin use was associated with a reduced risk of breast cancer recurrence (HRadj = 0.88 [95% CI: 0.82–0.96]). Regarding the pattern of recurrence, statin use was associated with a reduced risk of distant recurrence (HRadj = 0.86 [95% CI: 0.80–0.94]) but not loco-regional recurrence (HRadj = 0.97 [95% CI: 0.87–1.08]). Conclusion: In the MDCS, statin use was associated with a reduced risk of distant breast cancer recurrence, whereas no association between statin use and loco-regional breast cancer recurrence was found. This site-based difference in disease recurrence may be explained by statin's inhibition of epithelial-mesenchymal transition.
(Less)
- author
- Inasu, Maria LU ; Feldt, Maria LU ; Jernström, Helena LU ; Borgquist, Signe LU and Harborg, Sixten
- organization
- publishing date
- 2022-02
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Breast cancer, Cholesterol, Distant recurrences, Recurrence, Statins
- in
- Breast
- volume
- 61
- pages
- 6 pages
- publisher
- Churchill Livingstone
- external identifiers
-
- scopus:85122325512
- pmid:34995921
- ISSN
- 0960-9776
- DOI
- 10.1016/j.breast.2022.01.003
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2022 The Authors
- id
- beb9cdf1-40b3-43fb-8e4b-434d68fab37a
- date added to LUP
- 2022-02-24 14:36:00
- date last changed
- 2024-06-15 19:18:54
@article{beb9cdf1-40b3-43fb-8e4b-434d68fab37a,
abstract = {{<p>Background: Accumulating evidence suggests that statins have a beneficial effect on breast cancer prognosis. Previous studies have reported a positive association between statin use and breast cancer survival; however, the relationship between statin use and patterns of breast cancer recurrence remains unclear. Patients and methods: We identified all Malmö Diet and Cancer Study (MDCS) participants diagnosed with incident invasive breast cancer between 2005 and 2014. The follow-up period began at breast cancer diagnosis and continued until the first invasive breast cancer recurrence event, death, emigration or the end of the follow-up (June 8, 2020). We estimated incidence rates (IRs) of recurrence and fit Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CIs) for disease recurrence to compare post-diagnosis statin users with non-users. Results: The final study cohort consisted of 360 eligible patients with a median follow-up of 8.6 years. Overall, there were 71 recurrences in 2932 total person-years. According to statin use, there were 14 recurrences in 595 person-years among statin users, and 57 recurrences in 2337 person-years in non-users. Statin use was associated with a reduced risk of breast cancer recurrence (HR<sub>adj</sub> = 0.88 [95% CI: 0.82–0.96]). Regarding the pattern of recurrence, statin use was associated with a reduced risk of distant recurrence (HR<sub>adj</sub> = 0.86 [95% CI: 0.80–0.94]) but not loco-regional recurrence (HR<sub>adj</sub> = 0.97 [95% CI: 0.87–1.08]). Conclusion: In the MDCS, statin use was associated with a reduced risk of distant breast cancer recurrence, whereas no association between statin use and loco-regional breast cancer recurrence was found. This site-based difference in disease recurrence may be explained by statin's inhibition of epithelial-mesenchymal transition.</p>}},
author = {{Inasu, Maria and Feldt, Maria and Jernström, Helena and Borgquist, Signe and Harborg, Sixten}},
issn = {{0960-9776}},
keywords = {{Breast cancer; Cholesterol; Distant recurrences; Recurrence; Statins}},
language = {{eng}},
pages = {{123--128}},
publisher = {{Churchill Livingstone}},
series = {{Breast}},
title = {{Statin use and patterns of breast cancer recurrence in the Malmö Diet and Cancer Study}},
url = {{http://dx.doi.org/10.1016/j.breast.2022.01.003}},
doi = {{10.1016/j.breast.2022.01.003}},
volume = {{61}},
year = {{2022}},
}